Inovio Pharmaceuticals, Inc.
(NASDAQ : INO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
ABTAbbott Laboratories 1.26%86.020.8%$1219.54m
MDTMedtronic Plc 1.73%101.000.6%$1010.58m
TMOThermo Fisher Scientific, Inc. 3.38%317.521.0%$943.18m
ISRGIntuitive Surgical, Inc. -1.31%503.792.4%$746.21m
DHRDanaher Corp. 0.37%145.670.7%$729.51m
BDXBecton, Dickinson & Co. -1.00%247.511.1%$685.00m
SYKStryker Corp. 3.42%182.461.3%$646.77m
BSXBoston Scientific Corp. 4.84%36.831.1%$570.48m
EWEdwards Lifesciences Corp. 4.02%215.371.2%$464.56m
DXCMDexCom, Inc. 6.69%275.278.2%$423.23m
BAXBaxter International, Inc. 2.84%86.881.8%$384.95m
ZBHZimmer Biomet Holdings, Inc. -0.67%110.531.7%$302.74m
ALGNAlign Technology, Inc. 4.76%193.196.4%$302.48m
IDXXIDEXX Laboratories, Inc. 1.51%258.583.8%$271.63m
INOInovio Pharmaceuticals, Inc. -2.40%8.126.8%$228.32m

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.